Free Trial
NASDAQ:ZYXI

Zynex (ZYXI) Stock Price, News & Analysis

Zynex logo
$2.49 +0.08 (+3.32%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 -0.14 (-5.46%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Zynex Stock (NASDAQ:ZYXI)

Key Stats

Today's Range
$2.41
$2.58
50-Day Range
$1.66
$2.59
52-Week Range
$1.66
$10.62
Volume
207,789 shs
Average Volume
165,668 shs
Market Capitalization
$75.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Hold

Company Overview

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Zynex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

ZYXI MarketRank™: 

Zynex scored higher than 40% of companies evaluated by MarketBeat, and ranked 1990th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zynex has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zynex has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zynex's stock forecast and price target.
  • Earnings Growth

    Earnings for Zynex are expected to grow by 135.00% in the coming year, from $0.20 to $0.47 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zynex is -10.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zynex is -10.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zynex has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zynex's valuation and earnings.
  • Percentage of Shares Shorted

    22.40% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently increased by 2.05%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zynex does not currently pay a dividend.

  • Dividend Growth

    Zynex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.40% of the float of Zynex has been sold short.
  • Short Interest Ratio / Days to Cover

    Zynex has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zynex has recently increased by 2.05%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Zynex insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      49.28% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 29.68% of the stock of Zynex is held by institutions.

    • Read more about Zynex's insider trading history.
    Receive ZYXI Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

    ZYXI Stock News Headlines

    Here’s Why Zynex (ZYXI) Fell in Q1
    A new rule goes live in July — and the banks are quietly cashing in
    A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
    See More Headlines

    ZYXI Stock Analysis - Frequently Asked Questions

    Zynex's stock was trading at $8.01 at the start of the year. Since then, ZYXI stock has decreased by 68.9% and is now trading at $2.49.
    View the best growth stocks for 2025 here
    .

    Zynex Inc. (NASDAQ:ZYXI) posted its quarterly earnings data on Monday, April, 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.09. The company had revenue of $26.58 million for the quarter, compared to the consensus estimate of $30.83 million. Zynex had a negative trailing twelve-month return on equity of 23.70% and a negative net margin of 4.30%.
    Read the conference call transcript
    .

    Zynex's top institutional investors include Goldman Sachs Group Inc. (0.56%), Bank of New York Mellon Corp (0.53%), Janney Montgomery Scott LLC (0.49%) and Jane Street Group LLC (0.18%). Insiders that own company stock include Thomas Sandgaard, Joshua R Disbrow, Anna Lucsok and Daniel J Moorhead.
    View institutional ownership trends
    .

    Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Zynex investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Humana (HUM).

    Company Calendar

    Last Earnings
    4/28/2025
    Today
    6/20/2025
    Next Earnings (Estimated)
    7/23/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED PRODUCTS
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:ZYXI
    Fax
    N/A
    Employees
    770
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $6.00
    High Stock Price Target
    $8.00
    Low Stock Price Target
    $4.00
    Potential Upside/Downside
    +141.0%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    12.45
    P/E Growth
    N/A
    Net Income
    $2.99 million
    Pretax Margin
    -5.91%

    Debt

    Sales & Book Value

    Annual Sales
    $192.35 million
    Cash Flow
    $0.25 per share
    Price / Cash Flow
    9.87
    Book Value
    $1.12 per share
    Price / Book
    2.22

    Miscellaneous

    Free Float
    15,337,000
    Market Cap
    $75.30 million
    Optionable
    Optionable
    Beta
    0.82
    12 Stocks Corporate Insiders are Abandoning Cover

    If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

    Get This Free Report

    This page (NASDAQ:ZYXI) was last updated on 6/20/2025 by MarketBeat.com Staff
    From Our Partners